TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31542757
Drug: CPPOpt Guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPPOpt Guided Therapy (automated CPP target based on cerebrovascular reactivity)
Study: 24958326
Drug: Empagliflozin 50
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 50 mg
Study: 16979793
Drug: Alcohol-based waterless
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-based waterless scrub solution (ABWL)
Study: 16979793
Drug: Brush-based iodine
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush-based iodine solution (BBIS)
Study: 16979793
Drug: Alcohol-based water-aided
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-based water-aided scrub solution (ABWA)
Study: 9173664
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three solutions
Study: 12520092
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in beta(1)- or beta(2)-adrenergic receptor mRNA or protein
Study: 7806681
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (Augmentin or clindamycin) with scaling and rootplaning
Study: 7806681
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy with scaling and rootplaning
Study: 2588997
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of plain 0.5% bupivacaine
Study: 2588997
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of plain 0.5% bupivacaine
Study: 2588997
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of plain 0.5% bupivacaine
Study: 23179201
Drug: CHO constituent
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO constituent (50 g)
Study: 23179201
Drug: New DSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: New DSF (400 ml)
Study: 23179201
Drug: Control product
Normalized name: Patch test control product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control product (400 ml)
Study: 21948951
Drug: Patient-controlled local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled local analgesia (PCLA): self‐administration of 10 ml of ropivacaine 2 mg ml⁻¹ via the intra‐abdominal catheter for 48 h.
Study: 21948951
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA): infusion of 10 ml h⁻¹ of ropivacaine 1 mg ml⁻¹, fentanyl 2 μg ml⁻¹, and epinephrine 2 μg ml⁻¹ epidurally for 48 h.
Study: 19430766
Drug: Aqueous extract
Normalized name: green tea aqueous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous extract of Kava (5 tablets per day containing 250 mg of kavalactones/day)
Study: 1414179
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate and 2-chloroprocaine followed by continuous bupivacaine epidural infusion
Study: 1414179
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline and 2-chloroprocaine followed by continuous bupivacaine epidural infusion
Study: 27125818
Drug: SSRI prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI prescribing prior to psychological treatment
Study: 17873306
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg three times a day orally) and alpha-tocopherol (300 mg twice a day orally) during radiotherapy, followed by 400 mg once a day and 300 mg once a day for 3 months after radiotherapy.
Study: 10093981
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (intravenous methylprednisolone 1 g per day for 3 consecutive days at the beginning of months 1, 3, and 5, plus oral prednisone 0.5 mg/kg on alternate days for 6 months)
Study: 17611080
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy alone
Study: 2257861
Drug: Drug A
Normalized name: Drug additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A once daily in the evening
Study: 2257861
Drug: Drug A
Normalized name: Drug additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A b.d.
Study: 2257861
Drug: Drug B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug B b.d.
Study: 2257861
Drug: Drug A
Normalized name: Drug additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A b.d. and Drug B b.d.
Study: 25560201
Drug: Fluoxetine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (selective serotonin reuptake inhibitor) for 3 weeks
Study: 18373121
Drug: 2 cc
Normalized name: Bag Reclosable 2 cc 2X8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cc of fibrin glue intraoperatively
Study: 14750421
Drug: Hydacorn (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydacorn (1 mg dihydroergotamine, 40 mg caffeine, 100 mg diphenylhydantoine)
Study: 8238826
Drug: Fentanyl/bupivacaine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl/bupivacaine (2.5 micrograms.ml‐1 of fentanyl)
Study: 8238826
Drug: Sufentanil/bupivacaine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil/bupivacaine (0.25 micrograms.ml‐1 of sufentanil)
Study: 27491663
Drug: Electronically delivered,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronically delivered, multicomponent interventions including feedback of antibiotic prescribing reports, educational tools, and a webinar for 12 months.
Study: 11605101
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg alcohol
Study: 7862844
Drug: 0.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 g/kg alcohol
Study: 20838118
Drug: rFVIIa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (200 μg/kg initially; 100 μg/kg at 1 hour and 3 hours)
Study: 21689411
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg/day
Study: 8728351
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg for days 1-3, 20 mg for days 4-14)
Study: 1906716
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate inhalation aerosol preparation 1
Study: 1906716
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate inhalation aerosol preparation 2
Study: 28614197
Drug: Randomized Evaluation
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized Evaluation of Sedation Titration for Respiratory Failure protocol
Study: 28614197
Drug: Extracorporeal membrane
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal membrane oxygenation patients managed per Randomized Evaluation of Sedation Titration for Respiratory Failure protocol
Study: 22685670
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (400 mg) until delivery
Study: 17258626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium hydroxide and chlorhexidine [Ca(OH)2/CHX]
Study: 16322398
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 (BIAsp30) administered via multiple daily injections for 12 weeks
Study: 9637640
Drug: Lateral approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral approach to popliteal block (PB) with 40 ml 1.5% alkalinized mepivacaine with 1:200,000 epinephrine.
Study: 9637640
Drug: Posterior approach
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior approach to popliteal block (PB) with 40 ml 1.5% alkalinized mepivacaine with 1:200,000 epinephrine.
Study: 2973269
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide inhaled as a dry powder (40 micrograms)
Study: 28244205
Drug: Sacubitril-valsartan eligibility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril-valsartan eligibility criteria applied to patients on target doses of ACE inhibitors or ARBs
Study: 28244205
Drug: Sacubitril-valsartan eligibility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril-valsartan eligibility criteria applied to all patients regardless of background medication
Study: 28244205
Drug: Sacubitril-valsartan eligibility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril-valsartan eligibility criteria applied ignoring background medication
Study: 25819691
Drug: Oral eliglustat
Normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral eliglustat
Study: 23894336
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (risperidone and aripiprazole)
Study: 21199699
Drug: 2009 A/H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009 A/H1N1 MF59‐adjuvanted influenza vaccine administered simultaneously with seasonal virosomal‐adjuvanted influenza vaccine
Study: 21199699
Drug: 2009 A/H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009 A/H1N1 MF59‐adjuvanted influenza vaccine administered sequentially with seasonal virosomal‐adjuvanted influenza vaccine
Study: 21199699
Drug: Seasonal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal vaccine administered alone
Study: 21199699
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of pandemic and seasonal vaccines
Study: 11600556
Drug: Nateglinide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (60 mg) premeal (‐10,‐1 min)
Study: 11600556
Drug: Nateglinide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (60 mg) postmeal (+10 min)
Study: 11600556
Drug: Nateglinide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (60 mg) before meals (10 min before)
Study: 11600556
Drug: Nateglinide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (60 mg) after meals (10 min after)
Study: 7981071
Drug: OND/MPD (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: OND/MPD (8 mg OND i.v. injection and 120 mg MPD i.v. injection before chemotherapy, followed by 8 mg OND tablet and 16 mg MPD tablet orally for 3-5 days)
Study: 7981071
Drug: OND (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: OND (8 mg OND plus placebo i.v. injection before chemotherapy, followed by 8 mg OND tablet and placebo orally for 3-5 days)
Study: 30610502
Drug: Combined chitosan
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chitosan and Dan-shen injection
Study: 16919531
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg/d, 12 weeks)
Study: 11371410
Drug: Heat-killed Mycobacterium
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed Mycobacterium vaccae (0.5 mg)
Study: 11371410
Drug: Delipidated deglycolipidated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delipidated deglycolipidated Mycobacterium vaccae (DDMV) (0.05 mg)
Study: 31364105
Drug: Vaginal Soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Soft gels technology
Study: 28850362
Drug: Oxycodone 15mg
Normalized name: oxycodone hydrochloride 15 MG [Roxicodone]
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 15mg
Study: 26083699
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) instructed not to change daily routines and not allowed to ski
Study: 18326964
Drug: Low-dose diuretic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose diuretic
Study: 12747879
Drug: ICL670 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICL670 at 10 mg x kg(‐1) x day(‐1)
Study: 12747879
Drug: ICL670 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICL670 at 20 mg x kg(‐1) x day(‐1)
Study: 12747879
Drug: ICL670 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICL670 at 40 mg x kg(‐1) x day(‐1)
Study: 6397330
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide plus 50 mg triamterene
Study: 2897305
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide plus 5 mg amiloride
Study: 26051494
Drug: Inositol-enriched beverage
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol-enriched beverage (IEB) containing 2.23 g of inositols in 250 ml
Study: 25456755
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day atorvastatin
Study: 20830491
Drug: Midazolam group
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam group (50 μg/kg midazolam added to 3 mg/kg lidocaine 2% w/v)
Study: 20830491
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 mg/kg lidocaine 2% w/v diluted with saline to 40 ml)
Study: 12479119
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone
Study: 12479119
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment + Viagra
Study: 9656089
Drug: Computer-administered rating
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-administered rating scales (LSAS, BSPS, Fear Questionnaire)
Study: 9656089
Drug: Computer-administered rating
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-administered rating scales
Study: 27654852
Drug: PR1 peptide
Normalized name: PROTEINASE 3 PR1 PEPTIDE
DrugBank: PR1 leukemia peptide vaccine (DB15276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR1 peptide vaccine (0.25, 0.5 or 1.0 mg, administered subcutaneously every 3 weeks)
Study: 27654852
Drug: PR1 peptide
Normalized name: PROTEINASE 3 PR1 PEPTIDE
DrugBank: PR1 leukemia peptide vaccine (DB15276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR1 peptide vaccine
Study: 20128231
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with monomeric allergoid at a dosage of 1000 AU five times a week for two years
Study: 26875905
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drug therapy)
Study: 1388220
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined oestradiol valerate/cyproterone acetate (2 mg E2V + 1 mg CPA daily)
Study: 3895386
Drug: Psychotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy combined with medical treatment for IBS
Study: 3895386
Drug: Psychotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy combined with medical treatment for PUD
Study: 3895386
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only for IBS
Study: 3895386
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only for PUD
Study: 25659440
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administration: bolus dose of 15 mg/kg 10 min before tourniquet inflation, intra-articular administration of 3 grams 10 min before tourniquet deflation, IV infusion of 10 mg/kg/h for 3 h after completion on the second side.
Study: 25058218
Drug: Everolimus, 7.5
Normalized name: Everolimus, 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus, 7.5 mg/d
Study: 22334770
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg
Study: 22334769
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol fumarate (MF/F) 200/10 μg
Study: 19243713
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/d for 8 weeks
Study: 19243713
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/d for 8 weeks (subgroup of clinically responsive patients)
Study: 17435976
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of ACEI therapy (premed group)
Study: 17435976
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of ACEI therapy (withdrawal group)
Study: 15385353
Drug: Standard propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard propofol LCT with 20 mg lidocaine (group L; n = 113)
Study: 15385353
Drug: Standard propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard propofol LCT with 20 mg lidocaine (group L)
Study: 11238801
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (AGE) at doses between 2.4 and 7.2 g/d
Study: 11238801
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (AGE) at 7.2 g/d
Study: 7639417
Drug: L-propionylcarnitine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionylcarnitine (300 mg)
Study: 7639417
Drug: L-propionylcarnitine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionylcarnitine (600 mg)
Study: 7639417
Drug: L-propionylcarnitine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionylcarnitine (1200 mg)
Study: 2502040
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH) 20 mg p.o. (five doses during 30 hr preceding ethanol intake)
Study: 2502040
Drug: Ethanol 1
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 1 g/kg p.o. during 1 hr
Study: 31535460
Drug: l-arginine (ARG:
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine (ARG: 3.2 g)
Study: 31535460
Drug: wheat protein
Normalized name: Wheat protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: wheat protein hydrolysate (WPH: 2 g) + l-arginine (ARG: 3.2 g)
Study: 15001607
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone enanthate (1 mg/kg) and letrozole (2.5 mg orally once a day for 0-12 months)
Study: 11396248
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (SH) 2 x 7500 U s.c.
Study: 11396248
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) Dalteparin 1 x 5000 anti-Xa U s.c. once daily.
Study: 30633660
Drug: Glycine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (0.8 g/kg weekly for 12 weeks)
Study: 30633660
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching to glycine, provided in bottles with mixed in solution)
Study: 27077672
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rosiglitazone and rhGH
Study: 25051839
Drug: Silibinin combined
Normalized name: Silibinin
DrugBank: Silibinin (DB09298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silibinin combined with Ruangan pills
Study: 22270273
Drug: Lubricating gel
Normalized name: Via Moisturizer For Her Lubricating Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubricating gel (0.3 mL)
Study: 22270273
Drug: Water (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (3 mL)
Study: 19241078
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus 500 mg zosuquidar.3HCl (DZ)
Study: 21352110
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) for 12 months
Study: 15187819
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (2 g orally in effervescent tablets)
Study: 15187819
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral in effervescent tablets)
Study: 10789607
Drug: Perceived treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived treatment improvement
Study: 8902254
Drug: Magnesium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (10 mmol twice-daily)
Study: 1862029
Drug: 10% sulfur
Normalized name: SULFUR 10 g in 100 g TOPICAL SOAP [Dermaharmony 10% Sulfur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sulfur in cold cream
Study: 6140811
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (40 mg X 2)
Study: 19700442
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg i.v.